Literature DB >> 4330810

Myasthenia gravis and myasthenic syndromes treated with prednisone.

M Kjaer.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1971        PMID： 4330810     DOI： 10.1111/j.1600-0404.1971.tb07501.x

Source DB:  PubMed          Journal:  Acta Neurol Scand        ISSN： 0001-6314            Impact factor:   3.209


× No keyword cloud information.
  4 in total

1.  Controversies about the treatment of myasthenia gravis.

Authors:  L P Rowland
Journal:  J Neurol Neurosurg Psychiatry       Date:  1980-07       Impact factor: 10.154

2.  Treatment of myasthenia gravis. Report on 139 patients.

Authors:  C Scoppetta; P Tonali; A Evoli; P David; F Crucitti; M L Vaccario
Journal:  J Neurol       Date:  1979       Impact factor: 4.849

Review 3.  Exacerbation of myasthenia gravis following corticosteroid treatment: what is the evidence? A systematic review.

Authors:  Itay Lotan; Mark A Hellmann; Adi Wilf-Yarkoni; Israel Steiner
Journal:  J Neurol       Date:  2020-10-16       Impact factor: 6.682

4.  Intravenous immunoglobulins may prevent prednisone-exacerbation in myasthenia gravis.

Authors:  Laura Díez-Porras; Christian Homedes; Maria Antonia Alberti; Valentina Vélez-Santamaría; Carlos Casasnovas
Journal:  Sci Rep       Date:  2020-08-11       Impact factor: 4.379
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.